Evropska unija -
slovenščina -
EMA (European Medicines Agency)
zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemija, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
lerkanidipin arrow 20 mg filmsko obložene tablete
arrow generics limited - lerkanidipin - filmsko obložena tableta - lerkanidipin 18,8 mg / 1 tableta - lerkanidipin
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
esmocard lyo 2500 mg prašek za koncentrat za raztopino za infundiranje
orpha-devel handels und vertriebs gmbh - esmololijev klorid - prašek za koncentrat za raztopino za infundiranje - esmololijev klorid 2500 mg / 1 viala - esmolol
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
esmocard 10 mg/ml raztopina za injiciranje
orpha-devel handels und vertriebs gmbh - esmololijev klorid - raztopina za injiciranje - esmololijev klorid 10 mg / 1 ml - esmolol
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
ebixa
h. lundbeck a/s - memantinijev klorid - alzheimerjeva bolezen - druga zdravila proti demenciji - zdravljenje bolnikov z zmerno do hudo alzheimerjevo boleznijo.
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
atacand plus 32 mg/12,5 mg tablete
astrazeneca uk limited - hidroklorotiazid; cileksetilkandesartanat - tableta - hidroklorotiazid 12,5 mg / 1 tableta cileksetilkandesartanat32 mg / 1 tableta; cileksetilkandesartanat 32 mg / 1 tableta - kandesartan in diuretiki